Second Affiliated Hospital (Changzheng Hospital) of Naval Medical University, Shanghai, China.
Changhai Clinical Research Unit, Shanghai Changhai Hospital, Naval Medical University, Shanghai, China.
Drug Deliv. 2022 Dec;29(1):2100-2116. doi: 10.1080/10717544.2022.2094501.
Age is the strongest risk factor for Alzheimer's disease (AD). In recent years, the relationship between aging and AD has been widely studied, with anti-aging therapeutics as the treatment for AD being one of the mainstream research directions. Therapeutics targeting senescent cells have shown improvement in AD symptoms and cerebral pathological changes, suggesting that anti-aging strategies may be a promising alternative for AD treatment. Nanoparticles represent an excellent approach for efficiently crossing the blood-brain barrier (BBB) to achieve better curative function and fewer side effects. Thereby, nanoparticles-based anti-aging treatment may exert potent anti-AD therapeutic efficacy. This review discusses the relationship between aging and AD and the application and prospect of anti-aging strategies and nanoparticle-based therapeutics in treating AD.
年龄是阿尔茨海默病（AD）最强的危险因素。近年来，衰老与 AD 的关系已被广泛研究，以抗衰老治疗为 AD 治疗的主流研究方向之一。针对衰老细胞的治疗方法已显示出改善 AD 症状和脑病理变化的效果，这表明抗衰老策略可能是 AD 治疗的一种有前途的替代方法。纳米颗粒是一种高效穿透血脑屏障（BBB）的优异方法，可实现更好的治疗效果和更少的副作用。因此，基于纳米颗粒的抗衰老治疗可能具有强大的抗 AD 治疗效果。本综述讨论了衰老与 AD 的关系以及抗衰老策略和基于纳米颗粒的治疗方法在治疗 AD 中的应用和前景。
Zotero 插件
